The TGF-β pathway has also been targeted by therapeutic agents currently being tested in clinical trials (Korpal and Kang, 2010) and would be a candidate pathway to disrupt in combination with Notch signalling in the treatment of breast cancer bone metastasis. This evidence concerns the gene TGFB1 and breast carcinoma.